All In Biotech

Drug Trial Radar · NCT05775848

Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

112

Actual

Start

May 31, 2023

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
ML Bio Solutions, Inc.Industry
Sponsor type
Industry
First posted
Mar 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile. This will encompass the significant majority of existing diagnosed patients based upon the established epidemiology of the disease.

Conditions

  • Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

Interventions

  • BBP-418 (ribitol)Drug

    The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets.The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.

  • PlaceboOther

    A placebo matched for similar taste and appearance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in North Star Assessment for Limb Girdle Muscular Dystrophy following 36 months of treatment to assess efficacy of BBP-418 or placeboTime frame: 36 months
  2. Frequency and severity of treatment-emergent adverse events following 36 months of treatment to assess safety of BBP-418 or placeboTime frame: 36 months

Locations

21 sites in 8 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of California Irvine

    Irvine, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • University of Florida

    Gainesville, Florida

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • University of Minnesota, Twin Cities

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Oregon Health & Science University (OHSU) - Neurology Clinic - South Waterfront

    Portland, Oregon

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Children's Hospital of the Kings Daughters

    Norfolk, Virginia

  • Royal Brisbane and Women's Hospital,

    Brisbane, Queensland, Australia

  • Rigshospitalet, Neuromuscular Clinic and Research Unit

    Copenhagen, Denmark

  • Charité Universitätsmedizin Berlin and Max Delbrück Center

    Berlin, Germany

  • IRCCS Ca' Granda Ospedale

    Milan, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • Universitetssykehuset Nord-Norge, Department of Neurology

    Tromsø, Norway

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • International Centre for Life

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.